Institute of Medicine
Executive SummaryExecutive Officer Charles Miller, MD, is retiring after seven years as IOM's administrative director. IOM has appointed a search committee of two IOM staff and two outside medical reviewers to seek a replacement for Miller who will be leaving by year end. The search for a new executive officer, which began in July, will continue through Sept. 15 and OIM tentatively expects an appointment by the beginning of 1989.
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.